Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Across Clinical Development, Regulatory, and Medical Affairs as the Company Embarks on a Pivotal Trial for its Investigational, Allogeneic CD7-Targeted CAR-T Cell Therapy
ST. LOUIS and SAN DIEGO, Nov. 12, 2024 ( GLOBE NEWSWIRE ) -- Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, today announced the appointment of Cherry T.
| Ticker |
Sentiment |
Impact |
|
BGNE
|
Neutral
|
5 %
|
|
CRBU
|
Neutral
|
5 %
|
|
PFE
|
Neutral
|
5 %
|
|
BMY
|
Neutral
|
5 %
|
